Stempoint Capital’s AbbVie ABBV Stock Holding History

Stempoint Capital’s Portfolio ABBV Stock Details ABBV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-9,325	Closed	-$2.13M	–	83
2025 Q4	$2.13M	Buy	+9,325	New	+$2.12M	0.37%	58

Other funds holding ABBV

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Stempoint Capital's ABBV Position: Q1 2026 in Review

Stempoint Capital sold out of AbbVie (ABBV) in Q1 2026, closing a stake of 9,325 shares — an estimated $2.13M sold.

Stempoint Capital first reported a position in ABBV in Q4 2025 and held it in 1 quarter. The position peaked at $2.13M in Q4 2025. 4,097 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

Stempoint Capital reported no remaining AbbVie position as of Q1 2026 after selling out during the quarter.
Stempoint Capital sold 9,325 AbbVie shares in Q1 2026, an estimated $2.13M.
Stempoint Capital first reported a position in AbbVie in Q4 2025 and held it in 1 quarter.
Stempoint Capital's AbbVie position peaked at $2.13M in Q4 2025.
4,097 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on Stempoint Capital's 13F filing for Q1 2026, filed 15 May 2026.